Rapport Therapeutics (NASDAQ:RAPP) Sees Strong Trading Volume

Rapport Therapeutics (NASDAQ:RAPP) shares saw an uptick in trading volume on Wednesday . 106,601 shares were traded during trading, a decline of 45% from the previous session’s volume of 195,283 shares.The stock last traded at $21.00 and had previously closed at $20.98.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RAPP. TD Cowen initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective on the stock.

Rapport Therapeutics Trading Up 8.3 %

Insider Buying and Selling

In related news, Director James Healy acquired 44,032 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the purchase, the director now directly owns 40,851 shares in the company, valued at $1,001,666.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.